The effect of anticoagulant drugs on cancer.

Suppr

超能文献

作者信息

Falanga A

机构信息

Department of Hematology-Oncology, Ospedali Riuniti, Bergamo, Italy.

出版信息

J Thromb Haemost. 2004 Aug;2(8):1263-5. doi: 10.1111/j.1538-7836.2004.00868.x.

DOI:10.1111/j.1538-7836.2004.00868.x

PMID:15304028

Abstract

摘要

相似文献

The effect of anticoagulant drugs on cancer.

J Thromb Haemost. 2004 Aug;2(8):1263-5. doi: 10.1111/j.1538-7836.2004.00868.x.

Thrombosis and cancer: implications beyond Trousseau.

J Thromb Haemost. 2004 Aug;2(8):1261-2. doi: 10.1111/j.1538-7836.2004.00867.x.

Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices.

Dis Mon. 2005 Feb-Mar;51(2-3):150-7. doi: 10.1016/j.disamonth.2005.03.010.

Effects of anticoagulants on cancer: heparins.

Cancer Treat Res. 2009;148:259-75. doi: 10.1007/978-0-387-79962-9_15.

Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.

Cancer Chemother Pharmacol. 2013 Jul;72(1):65-73. doi: 10.1007/s00280-013-2169-y. Epub 2013 May 1.

Anticoagulants in cancer.

J Thromb Haemost. 2012 Nov;10(11):2230-41. doi: 10.1111/j.1538-7836.2012.04913.x.

Novel anticoagulant agents: introduction.

J Intern Med. 2003 Oct;254(4):308-12. doi: 10.1046/j.1365-2796.2003.01223.x.

Treatment of venous thrombosis.

Cancer Treat Res. 2009;148:243-57. doi: 10.1007/978-0-387-79962-9_14.

Low-molecular-weight heparin and survival in patients with malignant disease.

Cancer Control. 2005 Sep;12 Suppl 1:22-30. doi: 10.1177/1073274805012003S05.

Prophylaxis and treatment of venous thromboembolism in patients with cancer.

Intern Emerg Med. 2006;1(4):260-2. doi: 10.1007/BF02934757.

引用本文的文献

Non-Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer.

Oral Dis. 2025 Jun;31(6):1672-1683. doi: 10.1111/odi.15288. Epub 2025 Mar 3.

Heparin: 100 years of pleiotropic effects.

J Thromb Thrombolysis. 2016 May;41(4):636-43. doi: 10.1007/s11239-015-1261-z.

Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.

Patient Relat Outcome Meas. 2011 Jul;2:175-88. doi: 10.2147/PROM.S10099. Epub 2011 Nov 23.

The Quantification of Glycosaminoglycans: A Comparison of HPLC, Carbazole, and Alcian Blue Methods.

Open Glycosci. 2008 Jan 1;1:31-39. doi: 10.2174/1875398100801010031.

The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.

Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8. doi: 10.1073/pnas.0600979103. Epub 2006 Jun 12.

Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts.

BMC Cancer. 2005 Sep 21;5:121. doi: 10.1186/1471-2407-5-121.

Platelets and metastasis revisited: a novel fatty link.

J Clin Invest. 2004 Dec;114(12):1691-3. doi: 10.1172/JCI23823.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The effect of anticoagulant drugs on cancer.

J Thromb Haemost. 2004 Aug;2(8):1263-5. doi: 10.1111/j.1538-7836.2004.00868.x.

Thrombosis and cancer: implications beyond Trousseau.

J Thromb Haemost. 2004 Aug;2(8):1261-2. doi: 10.1111/j.1538-7836.2004.00867.x.

Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices.

Dis Mon. 2005 Feb-Mar;51(2-3):150-7. doi: 10.1016/j.disamonth.2005.03.010.

Effects of anticoagulants on cancer: heparins.

Cancer Treat Res. 2009;148:259-75. doi: 10.1007/978-0-387-79962-9_15.

Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.

Cancer Chemother Pharmacol. 2013 Jul;72(1):65-73. doi: 10.1007/s00280-013-2169-y. Epub 2013 May 1.

Anticoagulants in cancer.

J Thromb Haemost. 2012 Nov;10(11):2230-41. doi: 10.1111/j.1538-7836.2012.04913.x.

Novel anticoagulant agents: introduction.

J Intern Med. 2003 Oct;254(4):308-12. doi: 10.1046/j.1365-2796.2003.01223.x.

Treatment of venous thrombosis.

Cancer Treat Res. 2009;148:243-57. doi: 10.1007/978-0-387-79962-9_14.

Low-molecular-weight heparin and survival in patients with malignant disease.

Cancer Control. 2005 Sep;12 Suppl 1:22-30. doi: 10.1177/1073274805012003S05.

Prophylaxis and treatment of venous thromboembolism in patients with cancer.

Intern Emerg Med. 2006;1(4):260-2. doi: 10.1007/BF02934757.

引用本文的文献

Non-Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer.

Oral Dis. 2025 Jun;31(6):1672-1683. doi: 10.1111/odi.15288. Epub 2025 Mar 3.

Heparin: 100 years of pleiotropic effects.

J Thromb Thrombolysis. 2016 May;41(4):636-43. doi: 10.1007/s11239-015-1261-z.

Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.

Patient Relat Outcome Meas. 2011 Jul;2:175-88. doi: 10.2147/PROM.S10099. Epub 2011 Nov 23.

The Quantification of Glycosaminoglycans: A Comparison of HPLC, Carbazole, and Alcian Blue Methods.

Open Glycosci. 2008 Jan 1;1:31-39. doi: 10.2174/1875398100801010031.

The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.

Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8. doi: 10.1073/pnas.0600979103. Epub 2006 Jun 12.

Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts.

BMC Cancer. 2005 Sep 21;5:121. doi: 10.1186/1471-2407-5-121.

Platelets and metastasis revisited: a novel fatty link.

J Clin Invest. 2004 Dec;114(12):1691-3. doi: 10.1172/JCI23823.